Trial Profile

Relative Bioavailability of LY2963016 to LANTUS After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin glargine (Primary)
Indications Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
18 Nov 2019 Status changed from active, no longer recruiting to completed.
03 Oct 2019 Planned End Date changed from 27 Sep 2019 to 21 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com